加味香砂六君子汤对早中期肾性贫血患者血常规及血生化指标水平的影响

The Clinical Application Value of Recombinant Human Erythropoietin Combined with Additive Xiangshaliujunzi Decoction in Patients with Renal Anemia at Early and Middle Stage

目的:探讨重组人促红素联合加味香砂六君子汤在早中期肾性贫血患者中的临床应用价值。方法 :选取102例早中期肾性贫血患者为研究对象,采用随机数字表法分成联合组(A组51例)和对照组(B组51例)两组。A组采用皮下注射重组人促红素联合口服加味香砂六君子汤方案,B组予以皮下注射重组人促红素方案。比对两组患者治疗前后相关血常规、生化指标变化差异;行为期3个月随访,分析两组患者促红素总体用量、不良反应发生情况及复发情况差异。结果:治疗后两组患者RBC、Hb、Hct等血常规指标均较治疗前显著提高,BUN、SCr、Cys C、CRP等生化指标则较治疗前显著降低(P<0.05);其中A组患者各指标改善幅度均大于B组(P<0.05);A组促红素使用总剂量为(56 716.23±1 943.12)IU,显著低于B组的(82 346.26±2 153.12)IU,差异具有统计学意义(P<0.05);在为期3个月的随访中,A组不良反应发生率为7.8%,复发率为3.9%,均显著低于B组的23.5%和15.7%(P<0.05)。结论:对早中期肾性贫血患者予以重组人促红素+加味香砂六君汤联合治疗方案,疗效确切,可有效促进其红细胞生长、肾功能改善,值得临床推广。

Objective： To explore the clinical application value of recombinant human erythropoietin combined with additive Xiangshaliujunzi decoction in patients with renal anemia at early and middle stage. Methods： 102 Patients with renal anemia at early and middle stage were selected as the research objects. According to the random number table method, the objects were divided into the combined group（group A, n=51） and the control group（group B, n=51）. The group B were treated with subcutaneous injection of recombinant human erythropoietin（RH） scheme while the group A were treated with subcutaneous injection of recombinant human erythropoietin（RH） combined with oral additive Xiangshaliujunzi decoction scheme. The changes of blood routine and biochemical indexes in the two groups were compared before and after the treatment. With 3 months of follow-up during the behavior phase, the differences in total dosage of erythropoietin, occurrence and recurrence of adverse reactions were analyzed. Results：（1） After the treatment, blood routine indexes, such as RBC, Hb and Hct in the two groups were significantly higher than those before the treatment while SCr, Cys C, CRP and other biochemical indexes were significantly lower than those before the treatment（P〈0.05）. The improvement of each index in the group A was greater than that in the group B（P〈0.05）.（2） The total dosage of erythropoietin in the group A was（56 716.23±1 943.12） IU which was significantly lower than（82 346.26±2 153.12） IU in the group B, and the difference was statistically significant（P〈0.05）. During the period of 3 months of follow-up, the incidence rate of adverse reactions in the group A was 7.8% and the recurrence rate was 3.9%, which were significantly lower than 23.5% and 15.7% in the group B（P〈0.05）. Conclusion：To apply recombinant human erythropoietin combined with additive Xiangshaliujunzi decoction in patients with renal anemia at early and middle stage, the curative effect is accurate. It can effectively promote the growth of red cells and the improvement of renal function. It is worth clinical promotion.